Hong Kong is expanding clinical trials of histotripsy, a non-invasive treatment that uses focused ultrasound to destroy tumours, as the city seeks to establish a role in developing the technology for kidney cancer.
The CUHK Medical Centre, Gleneagles Hospital Hong Kong and Hong Kong Sanatorium & Hospital would begin trials involving 30 patients targeting kidney cancer, the Li Ka Shing Foundation said on Wednesday.
The trials mark the latest development in Hong Kong business tycoon Li Ka-shing’s biotech investments, which have drawn international attention. “Hong Kong [becomes] the first city in Asia to validate the safety and efficacy of treating renal diseases with histotripsy,” the tycoon’s charity said in an emailed statement.